- Current report filing (8-K)
December 21 2011 - 10:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): December 16, 2011
ALSERES PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
|
|
Delaware
|
|
0-6533
|
|
87-0277826
|
|
(State or Other Jurisdiction
of Incorporation
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
239 South Street, Hopkinton, Massachusetts
|
|
01748
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (508) 497-2360
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
TABLE OF CONTENTS
-2-
Item 1.01. Entry into Material Definitive Agreements.
On December 16, 2011 the Company purchased a total of 1,108,425 shares of the Company’s common stock held by certain shareholders of the Company
at $0.01 per share or a total of $11,084.25. 60,000 Shares were purchase from Robert Gipson (an affiliate of the Company). 530,000 shares were purchased from Thomas Gipson. 100,000 shares were purchased from Ingalls and Snyder Value Partners. 50,000
shares were purchased from Arthur Koenig. 218,425 shares were purchased from Nikos Monoyios. An additional 150,000 shares were purchased from other holders. The closing price for the Company’s stock on December 16 was $0.14 per share. The
price per share paid by the Company to the sellers represented a 93% discount to the market price for the shares.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
Alseres Pharmaceuticals, Inc.
|
|
|
|
|
|
|
Date: December 21, 2011
|
|
|
|
By:
|
|
/s/ Kenneth L. Rice, Jr.
|
|
|
|
|
|
|
|
Kenneth L. Rice, Jr.
|
|
|
|
|
|
|
|
Executive Vice President, Finance and Administration and Chief Financial Officer
|
-3-
Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Historical Stock Chart
From Dec 2024 to Jan 2025
Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Historical Stock Chart
From Jan 2024 to Jan 2025
